Incyte (INCY): Bellevue Group AG reduced its stake -130K shares
Bellevue Group AG reduced its stake in Incyte, per its Q3 2025 13F.
- 1.44M
- Shares reported · -130K vs prior quarter
- 2.5%
- Disclosed portfolio weight
- $122M
- Reported value
- Holdings as of
- Sep 30, 2025
- Filed
- Nov 14, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 16, 2025InsiderOfficer sold ~$23K of INCY shares in the open market
- Sep 18, 2025FDAFDA drug approval: Opzelura
- Sep 30, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 30, 2025, the Board of Directors of Incyte Corporation (the “Company”) appointed Thomas Tray, the Company’s current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025.”
- Oct 2, 2025InsiderOfficer sold ~$53K of INCY shares in the open market
- Oct 3, 2025InsiderOfficer sold ~$299K of INCY shares in the open market
- Oct 15, 2025InsiderOfficer sold ~$24K of INCY shares in the open market
- Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 7.8%
- Oct 28, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 3, 2025InsiderOfficer sold ~$289K of INCY shares in the open market
- Nov 4, 2025InsiderOfficer sold ~$61K of INCY shares in the open market
- Nov 5, 2025InsiderOfficer sold ~$535K of INCY shares in the open market
- Nov 10, 20255% stakeSTATE STREET CORPORATION reported a passive stake (13G) of 5.0%
- Nov 10, 2025Insider · Their largest sale since 2017Director sold ~$19.8M of INCY shares in the open market
What came next
- Nov 17, 2025InsiderOfficer sold ~$29K of INCY shares in the open market
- Nov 21, 2025InsiderOfficer sold ~$17K of INCY shares in the open market
- Nov 24, 2025InsiderOfficer sold ~$62K of INCY shares in the open market
- Dec 1, 2025InsiderOfficer sold ~$263K of INCY shares in the open market
- Dec 2, 2025Insider · 8 days before an 8-KOfficer sold ~$2.06M of INCY shares in the open market
- Dec 10, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately.”
- Dec 10, 2025InsiderOfficer sold ~$531K of INCY shares in the open market
- Dec 11, 2025InsiderOfficer sold ~$24K of INCY shares in the open market
- Dec 16, 2025Insider · 1 personInsiders: 2 sales (~$5.3M)
- Dec 17, 2025FDAFDA drug approval: Zynyz
- Dec 17, 2025InsiderOfficer sold ~$420K of INCY shares in the open market
- Dec 18, 2025InsiderOfficer sold ~$59K of INCY shares in the open market
- Dec 19, 2025InsiderOfficer sold ~$277K of INCY shares in the open market
- Jan 5, 2026InsiderOfficer sold ~$1.59M of INCY shares in the open market
- Jan 7, 2026InsiderOfficer sold ~$1.18M of INCY shares in the open market
- Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 10, 20265% stakeFelix J. Baker filed an activist stake (13D) of 15.7%
- Feb 19, 2026InsiderOfficer sold ~$1.88M of INCY shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Incyte
For Incyte, OQRO holds 24 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its INCY page.
How this filing works
Explore the data
Common questions
What does this filing report about Incyte (INCY) stock?
Bellevue Group AG reduced its stake in Incyte, per its Q3 2025 13F. Now 1.44M shares, $122M reported value, 2.5% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Sep 30, 2025. Filed: Nov 14, 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Incyte recently?
For Incyte, OQRO holds 24 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the INCY page.
Does this mean INCY stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Incyte
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 17, 2026
- SEC Form 4Nov 17, 2026
- SEC Form 4Nov 17, 2026
Everything OQRO holds on this company is on its INCY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
